Last reviewed · How we verify
HLCM051
HLCM051 is a small molecule targeting the SGLT2 receptor.
HLCM051 is a small molecule targeting the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | HLCM051 |
|---|---|
| Sponsor | Healios K.K. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, HLCM051 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin, which are used to treat type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome (PHASE2)
- Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HLCM051 CI brief — competitive landscape report
- HLCM051 updates RSS · CI watch RSS
- Healios K.K. portfolio CI